HDL-cholesterol and prediction of coronary heart disease: Modified by physical fitness?

Gordon, 1989, High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies, Circulation, 79, 8, 10.1161/01.CIR.79.1.8 Assmann, 1996, High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The procam experience and pathophysiological implications for reverse cholesterol transport, Atherosclerosis, 124, S11, 10.1016/0021-9150(96)05852-2 Stensvold, 1992, High-density lipoprotein cholesterol and coronary, cardiovascular and all cause mortality among middle-aged Norwegian men and women, Eur Heart J, 13, 1155, 10.1093/oxfordjournals.eurheartj.a060331 Marrugat, 1996, Amount and intensity of physical activity, physical fitness, and serum lipids in men. The marathom investigators, Am J Epidemiol, 143, 562, 10.1093/oxfordjournals.aje.a008786 Baruth, 2011, Changes in CVD risk factors in the activity counseling trial, Int J Gen Med, 4, 53, 10.2147/IJGM.S15686 Kodama, 2007, Effect of aerobic exercise training on serum levels of high-density lipoprotein cholesterol: a meta-analysis, Arch Intern Med, 167, 999, 10.1001/archinte.167.10.999 Lakka, 1992, Physical activity and serum lipids: a cross-sectional population study in eastern Finnish men, Am J Epidemiol, 136, 806, 10.1093/aje/136.7.806 Leon, 2001, Response of blood lipids to exercise training alone or combined with dietary intervention, Med Sci Sports Exerc, 33, S502, 10.1097/00005768-200106001-00021 Tambalis, 2009, Responses of blood lipids to aerobic, resistance, and combined aerobic with resistance exercise training: a systematic review of current evidence, Angiology, 60, 614, 10.1177/0003319708324927 Erikssen, 1998, Changes in physical fitness and changes in mortality, Lancet, 352, 759, 10.1016/S0140-6736(98)02268-5 Sandvik, 1993, Physical fitness as a predictor of mortality among healthy, middle-aged Norwegian men, N Engl J Med, 328, 533, 10.1056/NEJM199302253280803 Barter, 2004, Antiinflammatory properties of HDL, Circ Res, 95, 764, 10.1161/01.RES.0000146094.59640.13 Mineo, 2006, Endothelial and antithrombotic actions of HDL, Circ Res, 98, 1352, 10.1161/01.RES.0000225982.01988.93 Wannamethee, 2002, Physical activity and hemostatic and inflammatory variables in elderly men, Circulation, 105, 1785, 10.1161/01.CIR.0000016346.14762.71 Olchawa, 2004, Physical fitness and reverse cholesterol transport, Arterioscler Thromb Vasc Biol, 24, 1087, 10.1161/01.ATV.0000128124.72935.0f Kraus, 2002, Effects of the amount and intensity of exercise on plasma lipoproteins, N Engl J Med, 347, 1483, 10.1056/NEJMoa020194 Erikssen, 1976, False positive diagnostic tests and coronary angiographic findings in 105 presumably healthy males, Circulation, 54, 371, 10.1161/01.CIR.54.3.371 Burstein, 1970, Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions, J Lipid Res, 11, 583, 10.1016/S0022-2275(20)42943-8 Stein, 1978, Development and evaluation of a method for quantitation of plasma high-density-lipoprotein cholesterol, Clin Chem, 24, 1112, 10.1093/clinchem/24.7.1112 Wannamethee, 2009, Circulating inflammatory and hemostatic biomarkers are associated with risk of myocardial infarction and coronary death, but not angina pectoris, in older men, J Thromb Haemost, 7, 1605, 10.1111/j.1538-7836.2009.03574.x Ingelsson, 2007, Clinical utility of different lipid measures for prediction of coronary heart disease in men and women, JAMA, 298, 776, 10.1001/jama.298.7.776 Lewington, 2007, Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths, Lancet, 370, 1829, 10.1016/S0140-6736(07)61778-4 Cooney, 2009, How much does HDL cholesterol add to risk estimation? A report from the score investigators, Eur J Cardiovasc Prev Rehabil, 16, 304, 10.1097/HJR.0b013e3283213140 Ridker, 2008, Rosuvastatin to prevent vascular events in men and women with elevated c-reactive protein, N Engl J Med, 359, 2195, 10.1056/NEJMoa0807646 Van Der Steeg, 2008, High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein a–i: significance for cardiovascular risk: the ideal and epic-norfolk studies, J Am Coll Cardiol, 51, 634, 10.1016/j.jacc.2007.09.060 Bonjer, 1966, Measurement of working capacity by assessment of the aerobic capacity in a single session, Fed Proc, 25, 1363 Rubins, 1999, Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans affairs high-density lipoprotein cholesterol intervention trial study group, N Engl J Med, 341, 410, 10.1056/NEJM199908053410604 Taylor, 2004, Arterial biology for the investigation of the treatment effects of reducing cholesterol (arbiter) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins, Circulation, 110, 3512, 10.1161/01.CIR.0000148955.19792.8D Waksman, 2010, A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome, J Am Coll Cardiol, 55, 2727, 10.1016/j.jacc.2009.12.067 Fayad, 2011, Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-plaque): a randomised clinical trial, Lancet Goldberg, 2001, Aha science advisory: wine and your heart: a science advisory for healthcare professionals from the nutrition committee, council on epidemiology and prevention, and council on cardiovascular nursing of the American heart association, Circulation, 103, 472, 10.1161/01.CIR.103.3.472 Williams, 1996, High-density lipoprotein cholesterol and other risk factors for coronary heart disease in female runners, N Engl J Med, 334, 1298, 10.1056/NEJM199605163342004